Stewart McCallum is Chief Medical Officer at Recro Pharma, Inc. (REPH). They have made 1 open-market trade across 1 company since 2016, most recently 2018-01-18.
CIK 0001659872
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $10K since 2016, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| REPH | 33,701 | $70K |
Shares reported on the most recent Form 4, priced at the 2018-01-22 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| REPH | BUY | 2016-05-26 | 2016-05-31 | $8.22 | $10K | -2.0% | -5.8% | +11.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.